BioSpace

With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave

Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.

By BioSpace

1 min read
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights